Targeting MET: Why, where and how?

Current Opinion in Pharmacology

Volumn 13, Issue 4, 2013, Pages 511-518

  Ghiso, Elena ^a   Giordano, Silvia ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMG 208; ANTINEOPLASTIC AGENT; CABOZANTINIB; CETUXIMAB; CRIZOTINIB; EMD 1204831; EMD 1214063; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FICLATUZUMAB; FORETINIB; GEFITINIB; GOLVATINIB; INCB 28060; LY 2875358; MGCD 265; ONARTUZUMAB; PANITUMUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAF PROTEIN; RAS PROTEIN; RILOTUMUMAB; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; TAK 701; TIVANTINIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VEMURAFENIB;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BRAIN CANCER; BREAST CANCER; CANCER RESISTANCE; COLON CANCER; COLORECTAL CANCER; COLORECTAL TUMOR; DIGESTIVE SYSTEM CANCER; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG SENSITIVITY; DRUG TARGETING; FEMALE GENITAL TRACT TUMOR; GENE AMPLIFICATION; GENE MUTATION; GLIOBLASTOMA; GLIOMA; HEAD AND NECK CANCER; HUMAN; KIDNEY CANCER; KIDNEY CARCINOMA; KIDNEY TUMOR; LARGE CELL LYMPHOMA; LIVER CELL CARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LYMPHOMA; MELANOMA; MESOTHELIOMA; METASTATIC MELANOMA; MOLECULARLY TARGETED THERAPY; MULTIPLE MYELOMA; OSTEOSARCOMA; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE TUMOR; PROTEIN EXPRESSION; RHABDOMYOSARCOMA; SIGNAL TRANSDUCTION; SOLID TUMOR; STOMACH CANCER; THYROID CARCINOMA; THYROID MEDULLARY CARCINOMA;

EID: 84885958991     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2013.05.018     Document Type: Review

References (52)

1. Weinstein IB, Joe AK: Mechanisms of disease: oncogene addiction - a rationale for molecular targeting in cancer therapy. Nat Clin Pract Oncol 2006, 3:448-457. (Pubitemid 44203817)
2. Gschwind A, Fischer OM, Ullrich A: The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer 2004, 4:361-370. (Pubitemid 38579482)
3. Sierra JR, Cepero V, Giordano S: Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy. Mol Cancer 2010, 9:75.
4. Cepero V, Sierra JR, Giordano S: Tyrosine kinases as molecular targets to inhibit cancer progression and metastasis. Curr Pharm Des 2010, 16:1396-1409.
5. Migliore C, Giordano S: Molecular cancer therapy: can our expectation be MET? Eur J Cancer 2008, 44:641-651.
6. Corso S, Giordano S: Cell autonomous and non-cell autonomous mechanisms of HGF/MET-driven resistance to targeted therapies: from basic research to a clinical perspective. Cancer Discov 2013. (in press).
7. Cooper CS, Park M, Blair DG, Tainsky MA, Huebner K, Croce CM, Vande Woude GF: Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature 1984, 311:29-33. (Pubitemid 14065275)
8. Bottaro DP, Rubin JS, Faletto DL, Chan AM, Kmiecik TE, Vande Woude GF, Aaronson SA: Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 1991, 251:802-804. (Pubitemid 21926175)
9. Naldini L, Vigna E, Narsimhan RP, Gaudino G, Zarnegar R, Michalopoulos GK, Comoglio PM: Hepatocyte growth factor (HGF) stimulates the tyrosine kinase activity of the receptor encoded by the proto-oncogene c-MET. Oncogene 1991, 6:501-504. (Pubitemid 21924112)
10. Schmidt L, Duh FM, Chen F, Kishida T, Glenn G, Choyke P, Scherer SW, Zhuang Z, Lubensky I, Dean M et al.: Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 1997, 16:68-73. (Pubitemid 27198158)
11. Seruca R, Suijkerbuijk RF, Gartner F, Criado B, Veiga I, Olde- Weghuis D, David L, Castedo S, Sobrinho-Simoes M: Increasing levels of MYC and MET co-amplification during tumor progression of a case of gastric cancer. Cancer Genet Cytogenet 1995, 82:140-145.
12. Cappuzzo F, Marchetti A, Skokan M, Rossi E, Gajapathy S, Felicioni L, Del GM, Sciarrotta MG, Buttitta F, Incarbone M et al.: Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. J Clin Oncol 2009, 27:1667-1674.
13. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J et al.: MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316:1039-1043. (Pubitemid 46799492)
14. Bean J, Brennan C, Shih JY, Riely G, Viale A, Wang L, Chitale D, Motoi N, Szoke J, Broderick S et al.: MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A 2007, 104:20932-20937.
15. Bardelli A, Corso S, Bertotti A, Hobor S, Valtorta E, Siravegna G, Sartore-Bianchi A, Scala E, Cassingena A, Zecchin D et al.: Amplification of the MET receptor drives resistance to anti- EGFR therapies in colorectal cancer. Cancer Discov. 2013, 3:658-673.
16. Peters S, Adjei AA: MET: a promising anticancer therapeutic target. Nat Rev Clin Oncol 2012, 9:314-326.
17. Kentsis A, Reed C, Rice KL, Sanda T, Rodig SJ, Tholouli E, Christie A, Valk PJ, Delwel R, Ngo V et al.: Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia. Nat Med 2012, 18:1118-1122.
18. Yano S, Yamada T, Takeuchi S, Tachibana K, Minami Y, Yatabe Y, Mitsudomi T, Tanaka H, Kimura T, Kudoh S et al.: Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort. J Thorac Oncol 2011, 6:2011-2017.
19. Minuti G, Cappuzzo F, Duchnowska R, Jassem J, Fabi A, O'Brien T, Mendoza AD, Landi L, Biernat W, Czartoryska- Arlukowicz B et al.: Increased MET and HGF gene copy numbers are associated with trastuzumab failure in HER2- positive metastatic breast cancer. Br J Cancer 2012, 107:793-799.
20. Straussman R, Morikawa T, Shee K, Barzily-Rokni M, Qian ZR, Du J, Davis A, Mongare MM, Gould J, Frederick DT et al.: Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 2012, 487:500-504.
21. Smolen GA, Sordella R, Muir B, Mohapatra G, Barmettler A, Archibald H, Kim WJ, Okimoto RA, Bell DW, Sgroi DC et al.: Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc Natl Acad Sci U S A 2006, 103:2316-2321. (Pubitemid 43271667)
22. Lutterbach B, Zeng Q, Davis LJ, Hatch H, Hang G, Kohl NE, Gibbs JB, Pan BS: Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival. Cancer Res 2007, 67:2081-2088. (Pubitemid 46424226)
23. Corso S, Migliore C, Ghiso E, De RG, Comoglio PM, Giordano S: Silencing the MET oncogene leads to regression of experimental tumors and metastases. Oncogene 2008, 27:684-693. (Pubitemid 351158907)
24. Lennerz JK, Kwak EL, Ackerman A, Michael M, Fox SB, Bergethon K, Lauwers GY, Christensen JG, Wilner KD, Haber DA et al.: MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol 2011, 29:4803-4810
25. Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG, Halmos B: EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005, 352:786-792. (Pubitemid 40271173)
26. Cepero V, Sierra JR, Corso S, Ghiso E, Casorzo L, Perera T, Comoglio PM, Giordano S: MET and KRAS gene amplification mediates acquired resistance to MET tyrosine kinase inhibitors. Cancer Res 2010, 70:7580-7590.
27. De RW, Claes B, Bernasconi D, De SJ, Biesmans B, Fountzilas G, Kalogeras KT, Kotoula V, Papamichael D, Laurent-Puig P et al.: Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapyrefractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010, 11:753-762.
28. Corso S, Ghiso E, Cepero V, Sierra JR, Migliore C, Bertotti A, Trusolino L, Comoglio PM, Giordano S: Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition. Mol Cancer 2010, 9:121.
29. Bollag G, Tsai J, Zhang J, Zhang C, Ibrahim P, Nolop K, Hirth P: Vemurafenib: the first drug approved for BRAF-mutant cancer. Nat Rev Drug Discov 2012, 11:873-886.
30. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I et al.: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004, 351:337-345. (Pubitemid 38944402)
31. Van CE, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, Canon JL, Van Laethem JL, Maurel J, Richardson G et al.: Openlabel phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007, 25:1658-1664. (Pubitemid 46797944)
32. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I et al.: Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010, 362:2380-2388.
33. Michieli P, Basilico C, Pennacchietti S, Maffe A, Tamagnone L, Giordano S, Bardelli A, Comoglio PM: Mutant Met-mediated transformation is ligand-dependent and can be inhibited by HGF antagonists. Oncogene 1999, 18:5221-5231. (Pubitemid 29460658)
34. Basilico C, Pennacchietti S, Vigna E, Chiriaco C, Arena S, Bardelli A, Valdembri D, Serini G, Michieli P: Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET. Clin Cancer Res 2013.
35. Katayama R, Aoyama A, Yamori T, Qi J, Oh-Hara T, Song Y, Engelman JA, Fujita N: Cytotoxic activity of Tivantinib (ARQ 197) is not due solely to c-MET inhibition. Cancer Res 2013.
36. Ou SH, Kwak EL, Siwak-Tapp C, Dy J, Bergethon K, Clark JW, Camidge DR, Solomon BJ, Maki RG, Bang YJ et al.: Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J Thorac Oncol 2011, 6:942-946.
37. Ma PC, Tretiakova MS, MacKinnon AC, Ramnath N, Johnson C, Dietrich S, Seiwert T, Christensen JG, Jagadeeswaran R, Krausz T et al.: Expression and mutational analysis of MET in human solid cancers. Genes Chromosomes Cancer 2008, 47:1025-1037.
38. Ma PC, Kijima T, Maulik G, Fox EA, Sattler M, Griffin JD, Johnson BE, Salgia R: c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res 2003, 63:6272-6281. (Pubitemid 37255174)
39. Ma PC, Jagadeeswaran R, Jagadeesh S, Tretiakova MS, Nallasura V, Fox EA, Hansen M, Schaefer E, Naoki K, Lader A et al.: Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res 2005, 65:1479-1488. (Pubitemid 40270177)
40. Jagadeeswaran R, Ma PC, Seiwert TY, Jagadeeswaran S, Zumba O, Nallasura V, Ahmed S, Filiberti R, Paganuzzi M, Puntoni R et al.: Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma. Cancer Res 2006, 66:352-361. (Pubitemid 43166042)
41. Krishnaswamy S, Kanteti R, Duke-Cohan JS, Loganathan S, Liu W, Ma PC, Sattler M, Singleton PA, Ramnath N, Innocenti F et al.: Ethnic differences and functional analysis of MET mutations in lung cancer. Clin Cancer Res 2009, 15:5714-5723.
42. Neklason DW, Done MW, Sargent NR, Schwartz AG, nton- Culver H, Griffin CA, Ahnen DJ, Schildkraut JM, Tomlinson GE, Strong LC et al.: Activating mutation in MET oncogene in familial colorectal cancer. BMC Cancer 2011, 11:424.
43. Tengs T, Lee JC, Paez JG, Zhao X, LaFramboise T, Giannoukos G, Thomas RK: A transforming MET mutation discovered in nonsmall cell lung cancer using microarray-based resequencing. Cancer Lett 2006, 239:227-233. (Pubitemid 43974865)
44. Kim IJ, Park JH, Kang HC, Shin Y, Lim SB, Ku JL, Yang HK, Lee KU, Park JG: A novel germline mutation in the MET extracellular domain in a Korean patient with the diffuse type of familial gastric cancer. J Med Genet 2003, 40:e97.
45. Kong-Beltran M, Seshagiri S, Zha J, Zhu W, Bhawe K, Mendoza N, Holcomb T, Pujara K, Stinson J, Fu L et al.: Somatic mutations lead to an oncogenic deletion of met in lung cancer. Cancer Res 2006, 66:283-289. (Pubitemid 43166034)
46. Puri N, Ahmed S, Janamanchi V, Tretiakova M, Zumba O, Krausz T, Jagadeeswaran R, Salgia R: c-Met is a potentially new therapeutic target for treatment of human melanoma. Clin Cancer Res 2007, 13:2246-2253. (Pubitemid 46649894)
47. Lee JH, Han SU, Cho H, Jennings B, Gerrard B, Dean M, Schmidt L, Zbar B, Vande Woude GF: A novel germ line juxtamembrane Met mutation in human gastric cancer. Oncogene 2000, 19:4947-4953.
48. Schmidt L, Junker K, Nakaigawa N, Kinjerski T, Weirich G, Miller M, Lubensky I, Neumann HP, Brauch H, Decker J et al.: Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene 1999, 18:2343-2350. (Pubitemid 29192711)
49. Lorenzato A, Olivero M, Patane S, Rosso E, Oliaro A, Comoglio PM, Di Renzo MF: Novel somatic mutations of the MET oncogene in human carcinoma metastases activating cell motility and invasion. Cancer Res 2002, 62:7025-7030. (Pubitemid 35424097)
50. Moon YW, Weil RJ, Pack SD, Park WS, Pak E, Pham T, Karkera JD, Kim HK, Vortmeyer AO, Fuller BG et al.: Missense mutation of the MET gene detected in human glioma. Mod Pathol 2000, 13:973-977.
51. Park WS, Dong SM, Kim SY, Na EY, Shin MS, Pi JH, Kim BJ, Bae JH, Hong YK, Lee KS et al.: Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas. Cancer Res 1999, 59:307-310. (Pubitemid 29048858)
52. Di Renzo MF, Olivero M, Martone T, Maffe A, Maggiora P, Stefani AD, Valente G, Giordano S, Cortesina G, Comoglio PM: Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas. Oncogene 2000, 19:1547-1555. (Pubitemid 30175676)